FDA Approves Once-Daily, ‘Extended-Release’ Version of Zerit
The FDA on Tuesday approved a new, "extended-release" version of Zerit, which will be marketed as Zerit XR by Bristol-Myers Squibb. The new formulation has been shown to keep "measurable plasma concentrations" in patients for 24 hours following the once-a-day dose. Zerit XR is considered to be "more convenient" than the older formulation of the drug and could help HIV/AIDS patients more easily follow treatment guidelines (FDA release, 12/31).This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.